December 26, 2019
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 10 a.m. Read More
learn more
December 2, 2019
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
The program includes research grants and career development awards totaling more than $2 million over the next three years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program… Read More
learn more
November 26, 2019
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle’s presentation will begin at 12:30 p.m. EST. Mr. Doyle will also participate in one-on-one meetings with… Read More
learn more
November 20, 2019
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual… Read More
learn more
October 31, 2019
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next… Read More
learn more
October 16, 2019
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR)… Read More
learn more
October 1, 2019
Novocure to Report Third Quarter 2019 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine… Read More
learn more
September 9, 2019
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first presentation of in vitro… Read More
learn more
August 12, 2019
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation… Read More
learn more
August 6, 2019
Novocure to Participate in Three Upcoming Investor Conferences
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences. Pritesh Shah, Novocure’s Chief Commercial Officer, will participate in the Wedbush PacGrow Healthcare Conference on August 14, 2019, in New York City. Mr. Shah’s presentation will begin at 8:35 a.m. EDT. Read More
learn more